Agile Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Agile Therapeutics, Inc. is a women's healthcare company specializing in the research, development, and commercialization of prescription contraceptive products in the United States. Its primary product is Twirla, a once-weekly combination hormonal contraceptive patch delivering levonorgestrel and ethinyl estradiol via its proprietary Skinfusion transdermal system. The product is designed to offer women effective contraception without the need for daily pills or longer-acting methods. Agile is developing additional Twirla line extensions and novel products, including variants of the patch aimed at regulating withdrawal bleeding episodes and providing a progestin-only option for users who cannot use estrogen. Founded in 1997 and headquartered in Princeton, New Jersey, Agile Therapeutics operates primarily in the specialty drug manufacturing sector focused on women's health contraceptive solutions. Significant recent developments include Agile’s acquisition by Insud Pharma, S.L., through its U.S. subsidiary Exeltis USA, Inc., completed in August 2024 at an enterprise valuation of approximately $45 million. This acquisition expanded Exeltis's women’s health and contraceptive portfolio and marked Agile’s transition to an indirect subsidiary of Insud, resulting in the company’s delisting from public markets. Agile has benefited from a strategic infusion of capital via an $8 million line of credit as part of the transaction to support inventory and operational needs. The acquisition positions Agile for broader market access and enhanced resources to advance its contraceptive offerings. Additionally, Agile has reported strong revenue growth driven by increased demand for Twirla, reflecting a successful commercial rebound. Agile Therapeutics’s product offerings focus on contraceptive patches designed to meet unmet needs in women’s reproductive healthcare by providing flexible, non-daily contraception options. Twirla features a transdermal delivery system that combines low-dose estrogen and progestin, targeting women with BMI under 30. The company also supports user adherence and education through patient programs such as The Loop, which provides resources and nurse-educator support. Agile’s pipeline includes several Twirla regimen variations designed to optimize contraceptive efficacy and bleeding profiles, as well as a progestin-only patch for estrogen-intolerant women. The company’s operations and product development are centered in the U.S. market, leveraging its proprietary transdermal technology platform. In summary, Agile Therapeutics operates within the healthcare and specialty pharmaceutical sectors focused on women's contraceptive products, with a flagship transdermal contraceptive patch, Twirla, and a pipeline of product enhancements. The company’s strategic acquisition by Insud Pharma broadens its platform and market footprint, supporting continued growth and innovation in contraceptive solutions for women in the U.S. Agile Therapeutics is headquartered in Princeton, New Jersey, and was founded in 1997. It now functions as an indirect subsidiary of Insud Pharma through Exeltis USA, Inc. following the 2024 acquisition. The company’s commercial and research activities prioritize expanded contraceptive options that provide convenience and adherence benefits to women.
Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
Agile Leadership for Pharma and Biopharma Professionals in a Hybrid World: 2-Day Training Course (Online) November 18-19, 2024 - Become Competent and Familiar in a Range of Well-Recognised Leadership Techniques
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRX
AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
Agile Therapeutics Announces Delisting from Nasdaq
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
Why Is Agile Therapeutics (AGRX) Stock Up 87% Today?
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement & Provides Performance Update
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act's No-Cost Contraceptive Coverage Requirement
Top Penny Stocks To Buy Now? 4 To Watch Under $4
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
Agile Therapeutics, Inc. (AGRX) Q3 2023 Earnings Call Transcript